- Home
- CMMB vs PYPD Comparison
CMMB vs PYPD Comparison
Compare CMMB & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- PYPD
- Stock Information
- Founded
- CMMB 2004
- PYPD 2008
- Country
- CMMB Israel
- PYPD Israel
- Employees
- CMMB N/A
- PYPD N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- PYPD Medical/Dental Instruments
- Sector
- CMMB Health Care
- PYPD Health Care
- Exchange
- CMMB Nasdaq
- PYPD Nasdaq
- Market Cap
- CMMB N/A
- PYPD 16.5M
- IPO Year
- CMMB N/A
- PYPD 2020
- Fundamental
- Price
- CMMB $1.68
- PYPD $3.22
- Analyst Decision
- CMMB Strong Buy
- PYPD Strong Buy
- Analyst Count
- CMMB 3
- PYPD 2
- Target Price
- CMMB $7.33
- PYPD $12.00
- AVG Volume (30 Days)
- CMMB 87.3K
- PYPD 29.0K
- Earning Date
- CMMB 11-14-2024
- PYPD 02-12-2025
- Dividend Yield
- CMMB N/A
- PYPD N/A
- EPS Growth
- CMMB N/A
- PYPD N/A
- EPS
- CMMB N/A
- PYPD N/A
- Revenue
- CMMB N/A
- PYPD N/A
- Revenue This Year
- CMMB N/A
- PYPD N/A
- Revenue Next Year
- CMMB N/A
- PYPD N/A
- P/E Ratio
- CMMB N/A
- PYPD N/A
- Revenue Growth
- CMMB N/A
- PYPD N/A
- 52 Week Low
- CMMB $0.45
- PYPD $2.37
- 52 Week High
- CMMB $2.55
- PYPD $9.20
- Technical
- Relative Strength Index (RSI)
- CMMB 52.44
- PYPD 53.21
- Support Level
- CMMB $1.53
- PYPD $2.37
- Resistance Level
- CMMB $1.71
- PYPD $3.13
- Average True Range (ATR)
- CMMB 0.11
- PYPD 0.32
- MACD
- CMMB -0.01
- PYPD 0.05
- Stochastic Oscillator
- CMMB 39.47
- PYPD 64.89
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.